BioNTech SE (WBO:BNTX) Equity-to-Asset : 0.88 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is BioNTech SE Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. BioNTech SE's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €20,246 Mil. BioNTech SE's Total Assets for the quarter that ended in Dec. 2023 was €23,006 Mil. Therefore, BioNTech SE's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.88.

The historical rank and industry rank for BioNTech SE's Equity-to-Asset or its related term are showing as below:

WBO:BNTX' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.13 Med: 0.61 Max: 0.88
Current: 0.88

During the past 8 years, the highest Equity to Asset Ratio of BioNTech SE was 0.88. The lowest was -0.13. And the median was 0.61.

WBO:BNTX's Equity-to-Asset is ranked better than
82.47% of 1563 companies
in the Biotechnology industry
Industry Median: 0.66 vs WBO:BNTX: 0.88

BioNTech SE Equity-to-Asset Historical Data

The historical data trend for BioNTech SE's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioNTech SE Equity-to-Asset Chart

BioNTech SE Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Equity-to-Asset

Get a 7-Day Free Trial

0.62

0.59

0.75

0.86

0.88

BioNTech SE Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Equity-to-Asset	Get a 7-Day Free Trial															0.86	0.92	0.90	0.90	0.88

Competitive Comparison of BioNTech SE's Equity-to-Asset

For the Biotechnology subindustry, BioNTech SE's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioNTech SE's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioNTech SE's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where BioNTech SE's Equity-to-Asset falls into.

BioNTech SE Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

BioNTech SE's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	20245.9	/	23006.3
	=	0.88

BioNTech SE's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	20245.9	/	23006.3
	=	0.88

BioNTech SE (WBO:BNTX) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

BioNTech SE Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of BioNTech SE's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

BioNTech SE (WBO:BNTX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioNTech SE (WBO:BNTX) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

BNTX:USA BNTX:Mexico 0A3M:UK 22UA:Germany B1NT34:Brazil

Address

An der Goldgrube 12, Mainz, RP, DEU, D-55131

Website

https://www.biontech.de

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. COVID-19 vaccine Comirnaty is its first commercialized product.